Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B.
ALT, alanine aminotransferase
APRI, AST to platelet ratio index
AST, aspartate aminotransferase
CHB, chronic hepatitis B
CHC, chronic hepatitis C
CHD, chronic hepatitis D
CLDQ, Chronic Liver Disease Questionnaire
Chronic Liver Disease Questionnaire
DAA, direct-acting antivirals
EMA, European medicines agency
FACIT-F, Functional Assessment of Chronic Illness Therapy–Fatigue
FIB-4, Fibrosis-4
Functional Assessment of Chronic Illness Therapy–Fatigue
HRQoL, health-related quality of life
Health-related quality of life
IFN, interferon
LLOD, lower limit of detection
LLOQ, lower limit of quantification
NAs, nucleos(t)ide analogues
PROs, patient-reported outcomes
Viral hepatitis
WPAI, Work Productivity and Activity Impairment
Work Productivity Activity Impairment
pegIFN, pegylated interferon
Journal
JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
24
12
2020
revised:
08
03
2021
accepted:
09
03
2021
entrez:
27
5
2021
pubmed:
28
5
2021
medline:
28
5
2021
Statut:
epublish
Résumé
Health-related quality of life (HRQoL) determined by patient-reported outcomes (PROs) is impaired in chronic hepatitis B (CHB) and C patients, but there are no data regarding patients with chronic hepatitis D (CHD). The aim of this study was to assess PRO scores in untreated patients with CHD and compare them with those obtained for patients with CHB. Patients with CHD completed 3 PRO instruments (Chronic Liver Disease Questionnaire [CLDQ], Functional Assessment of Chronic Illness Therapy-Fatigue [FACIT-F], and Work Productivity and Activity Impairment [WPAI]), and the results were compared with those of patients mono-infected with CHB. In total, 125 patients were included: 43 with CHD and 82 with CHB. Overall, baseline PROs showed differences between both groups. Several assessments, such as the worry score from CLDQ ( In this first assessment in CHD, PROs recorded in patients with CHD showed a significant impairment in some domains of HRQoL questionnaires in comparison with those with CHB. Studies in larger cohorts with lengthier follow-up are needed to fully assess patient-reported quality of life over the course of CHD. Chronic hepatitis D (CHD) is a viral disease that causes rapid evolution to liver cirrhosis, amongst other severe complications, when compared to patients with chronic hepatitis B (CHB). Health-related quality of life in chronic hepatitis C and CHB has been reported widely, but no studies have been performed on patient-reported outcomes in patients with CHD. Results showed that CHD patients reported worse outcomes in psychological domains such as worry and emotional well-being, as well as in physical domains such as abdominal symptoms, physical well-being, and activity impairment in comparison with patients with CHB.
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
Health-related quality of life (HRQoL) determined by patient-reported outcomes (PROs) is impaired in chronic hepatitis B (CHB) and C patients, but there are no data regarding patients with chronic hepatitis D (CHD). The aim of this study was to assess PRO scores in untreated patients with CHD and compare them with those obtained for patients with CHB.
METHODS
METHODS
Patients with CHD completed 3 PRO instruments (Chronic Liver Disease Questionnaire [CLDQ], Functional Assessment of Chronic Illness Therapy-Fatigue [FACIT-F], and Work Productivity and Activity Impairment [WPAI]), and the results were compared with those of patients mono-infected with CHB.
RESULTS
RESULTS
In total, 125 patients were included: 43 with CHD and 82 with CHB. Overall, baseline PROs showed differences between both groups. Several assessments, such as the worry score from CLDQ (
CONCLUSIONS
CONCLUSIONS
In this first assessment in CHD, PROs recorded in patients with CHD showed a significant impairment in some domains of HRQoL questionnaires in comparison with those with CHB. Studies in larger cohorts with lengthier follow-up are needed to fully assess patient-reported quality of life over the course of CHD.
LAY SUMMARY
BACKGROUND
Chronic hepatitis D (CHD) is a viral disease that causes rapid evolution to liver cirrhosis, amongst other severe complications, when compared to patients with chronic hepatitis B (CHB). Health-related quality of life in chronic hepatitis C and CHB has been reported widely, but no studies have been performed on patient-reported outcomes in patients with CHD. Results showed that CHD patients reported worse outcomes in psychological domains such as worry and emotional well-being, as well as in physical domains such as abdominal symptoms, physical well-being, and activity impairment in comparison with patients with CHB.
Identifiants
pubmed: 34041466
doi: 10.1016/j.jhepr.2021.100280
pii: S2589-5559(21)00056-2
pmc: PMC8141931
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100280Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
MB and RE have served as a speaker and advisory board member for Gilead, Roche, and Arbutus. MRB has served as a speaker for AbbVie and Gilead. ZY has received research funds from Intercept, 10.13039/100004334Merck, 10.13039/100002491BMS, and 10.13039/100004340Siemens, and has served as consultant for Gilead, Terns, Viking, Intercept, Merck, Abbvie, Novartis, BMS, Shionogi, and Siemens. Please refer to the accompanying ICMJE disclosure forms for further details.
Références
BMC Public Health. 2019 Apr 29;19(1):457
pubmed: 31035994
Aliment Pharmacol Ther. 2018 Jan;47(2):259-267
pubmed: 29181842
Semin Liver Dis. 2018 Feb;38(1):66-72
pubmed: 29471567
Dig Dis Sci. 2016 Apr;61(4):1186-96
pubmed: 26831489
J Hepatol. 2008 Dec;49(6):923-9
pubmed: 18929420
Eur J Public Health. 2019 Aug 1;29(4):634-639
pubmed: 30668855
Liver Int. 2019 Jan;39(1):54-59
pubmed: 29893462
Am J Gastroenterol. 2001 Jul;96(7):2199-205
pubmed: 11467653
Ann Hepatol. 2010 Oct-Dec;9(4):419-27
pubmed: 21057161
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
J Biomed Sci. 2015 Oct 20;22:92
pubmed: 26487087
J Viral Hepat. 2018 Aug;25(8):911-919
pubmed: 29577518
Aliment Pharmacol Ther. 2015 Aug;42(3):286-95
pubmed: 26059536
Aliment Pharmacol Ther. 2012 Mar;35(6):663-73
pubmed: 22273482
BMC Infect Dis. 2015 Jan 17;15:19
pubmed: 25596623
Gut. 2019 Mar;68(3):512-521
pubmed: 30228220
Liver Int. 2019 Oct;39(10):1837-1844
pubmed: 31173468
PLoS Negl Trop Dis. 2018 Apr 26;12(4):e0006377
pubmed: 29698488
J Hepatol. 2016 Apr;64(1 Suppl):S102-S116
pubmed: 27084031
BMC Womens Health. 2012 Nov 23;12:41
pubmed: 23173572
Gut. 1999 Aug;45(2):295-300
pubmed: 10403745
Hepatology. 1999 Aug;30(2):550-5
pubmed: 10421667
Cold Spring Harb Perspect Med. 2015 Jul 01;5(7):a021576
pubmed: 26134842
Aliment Pharmacol Ther. 2020 Jan;51(1):158-166
pubmed: 31721254
Clin Gastroenterol Hepatol. 2019 Jul;17(8):1641-1642.e1
pubmed: 30268565
Clin Gastroenterol Hepatol. 2016 Jan;14(1):156-64.e3
pubmed: 26241510
J Hepatol. 2020 Sep;73(3):523-532
pubmed: 32335166
J Hepatol. 2014 Mar;60(3):618-24
pubmed: 24240053
Sci Rep. 2017 Sep 19;7(1):11867
pubmed: 28928388
PLoS One. 2018 Oct 9;13(10):e0205277
pubmed: 30300395
J Viral Hepat. 2011 Jun;18(6):434-42
pubmed: 20546496
Hepatology. 1999 Jun;29(6 Suppl):7S-8S
pubmed: 10386075
J Hepatol. 2015 Apr;62(1 Suppl):S76-86
pubmed: 25920093
Gastroenterology. 2009 May;136(5):1629-38
pubmed: 19208358
J Clin Epidemiol. 2003 Jan;56(1):88-93
pubmed: 12589875
J Clin Gastroenterol. 2019 May/Jun;53(5):331-341
pubmed: 30702486
Sci Rep. 2020 Jun 25;10(1):10388
pubmed: 32587314
J Hepatol. 2007 Mar;46(3):420-31
pubmed: 17196293
Liver Int. 2019 Sep;39(9):1631-1640
pubmed: 30959554
Health Qual Life Outcomes. 2003 Dec 16;1:79
pubmed: 14678568
J Hepatol. 2013 Mar;58(3):593-608
pubmed: 23419824
J Hepatol. 1990;11 Suppl 1:S145-8
pubmed: 2079573
Int J Environ Res Public Health. 2018 Apr 11;15(4):
pubmed: 29641485
J Formos Med Assoc. 2008 Jun;107(6):454-62
pubmed: 18583216
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
PLoS One. 2019 May 3;14(5):e0215596
pubmed: 31050687
Qual Life Res. 2008 May;17(4):575-84
pubmed: 18389385
Eur J Intern Med. 2019 Dec;70:54-59
pubmed: 31530418
J Hepatol. 2014 Nov;61(5):1158-65
pubmed: 25010259
Liver Int. 2018 Oct;38(10):1849-1859
pubmed: 29377462